Trial reportJournal of the neurological sciences2008
Antioxidant use in Friedreich ataxia.
Trial report in Journal of the neurological sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Recent developments in Friedreich's ataxia: a state-of-the-art review.Brain communications · 2026Review
- Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?Antioxidants (Basel, Switzerland) · 2025Review
- Friedreich ataxia: clinical features and new developments.Neurodegenerative disease management · 2022Review
- Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia.Antioxidants (Basel, Switzerland) · 2020Review
- Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease.Neuronal signaling · 2018Review
- Milestones in Friedreich ataxia: more than a century and still learning.Neurogenetics · 2015Review
- Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.World journal of methodology · 2014Review
- Drug development for rare mitochondrial disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Redox processes in neurodegenerative disease involving reactive oxygen species.Current neuropharmacology · 2012Article
- Childhood ataxia: clinical features, pathogenesis, key unanswered questions, and future directions.Journal of child neurology · 2012Article
- Cardiac involvement in hereditary ataxias.Journal of child neurology · 2012Review
- NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.PloS one · 2011Article
- Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice.PloS one · 2011Article
- Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.Movement disorders : official journal of the Movement Disorder Society · 2010Article
- Pharmacotherapy for Friedreich ataxia.CNS drugs · 2009Review
- Predictors of progression in patients with Friedreich ataxia.Movement disorders : official journal of the Movement Disorder Society · 2008Article
- Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia.Human molecular genetics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
Abstract
Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.